NCT04552951

Effect of Vitamin D on Morbidity and Mortality of the COVID-19

Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infección Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Patients diagnosed of COVID-19 disease are randomized to receive a single dose of 100.000 IU of Cholecalciferol (Vitamin D arm) or no vitamin D (on top of the current medication used to treat COVID 19). Clinical, radiological and biochemical outcomes of COVID 19 disease as well as mortality are evaluated.

Detailed description

Efficacy parameters to compare both groups (vitamin D and No vitamin D). Time to reach undetectable levels of SARS COV2 Infection. Time of normalization of symptoms and clinical parameters. Time of normalization of radiological images. Time of normalization of biochemical markers. Time of normalization of molecular inflammatory markers. Transfer to the Intensive care Unit. Mortality rate.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	Cholecalciferol	Single doe of 100.000 IU

Timeline

• Start date: 2020-04-04
• Primary completion: 2020-09-14
• Completion: 2020-12-30
• First posted: 2020-09-17
• Last updated: 2020-09-17

Locations

1 site across 1 country: Spain